Precise Anti-Tumor Effect of a Metallopolysaccharide-Based Nanotheranostic: Turning Phototherapy into Programmed Chemotherapy

2022 ◽  
Author(s):  
Chengyuan Zhu ◽  
Zhengxi Guo ◽  
Aijia Yang ◽  
Bang-Ping Jiang ◽  
Hong Liang ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Residual Cancer

Phototheranostic, a regional-focused treatment, can endow cancer theranostic with low damage due to its spatial precision. However, precise elimination of residual cancer cells in laser-focused field and in non-laser-focused field...

scholarly journals Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer

2021 ◽  
Author(s):  
Dongbin Zhao ◽  
Pinli Yue ◽  
Tongbo Wang ◽  
Pei Wang ◽  
Qianqian Song ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Cancer Cells ◽  
Peritoneal Lavage ◽  
Peritoneal Dissemination ◽  
Lavage Fluid ◽  
Residual Cancer ◽  
Peritoneal Lavage Fluid ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Abstract Peritoneal dissemination (PD) is the major type of gastric cancer (GC) recurrence and leads to rapid death. Current approach cannot precisely determine which patients are at high risk of PD. In this study, we developed a technology to detect minimal residual cancer cells in peritoneal lavage fluid (PLF) samples by parallel profiling tumor-specific mutations. We applied the technology to a prospective cohort of 110 GC patients. The technology showed ultra-high sensitivity by successfully detecting all the 27 cases that developed PD. The minimal residual cancer cells in PLF was associated with an increased risk of PD (HR = 145.13; 95%CI = 20.20-18435.79; p < 0.001) and significantly shorter overall survival. In pathologically high-risk (T4) patients, the PLF mutation profiling model exhibited even greater specificity of 91% and positive predictive value of 88%, while retaining sensitivity of 100%. PLF cancer cell fraction remained the strongest independent predictor of PD and recurrence-free survival over pathologic diagnosis and cytological diagnosis in GC patients. This approach may help in the postsurgical management of GC patients by detecting PD far before the metastatic lesions grow to significant size detectable by conventional methods such as MRI and CT scanning.

scholarly journals Impact of dose reduction and treatment delay of neoadjuvant chemotherapy in gastric and esophageal adenocarcinoma

2019 ◽  
Author(s):  
David Borg ◽  
Charlotta Hedner ◽  
Karin Jirström ◽  
Anders Johnsson
Keyword(s):  
Neoadjuvant Chemotherapy ◽  
Cancer Cells ◽  
Esophageal Adenocarcinoma ◽  
Total Duration ◽  
Binary Logistic Regression ◽  
Residual Cancer ◽  
Treatment Delays ◽  
Histopathologic Response ◽  
Time To Recurrence ◽  
Kaplan Meier

Abstract Background Neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma is often hampered by toxicities and fragile patients resulting in dose reductions and/or treatment delays. The aim of this study was to assess how these treatment modifications affect outcome. Methods A series of 63 consecutive patients treated 2008-2014 with neoadjuvant EOX (epirubicin, oxaliplatin and capecitabine) and surgical resection, with or without adjuvant treatment, were reviewed. Chemotherapy dose index (DI), i.e. the ratio of actual to planned cumulative dose, and time index (TI), i.e. the ratio of planned to actual total duration, were calculated. Associations of neoadjuvant EOX DI and TI with histopathologic response were analysed with binary logistic regression. Time to recurrence (TTR) and overall survival (OS) were estimated using Kaplan-Meier analyses. Results Statistically significant associations were found between neoadjuvant EOX TI >= 0.95 and a major histopathologic response (0-10% residual cancer cells) and between neoadjuvant EOX DI >= 0.95 and a response with 0-50% residual cancer cells. Significantly improved TTR and OS were seen in patients with a major histopathologic response. Conclusions Our results suggest that treatment delays of neoadjuvant chemotherapy in gastric or esophageal adenocarcinoma should be avoided in order to achieve a major response.

Independent Prognostication and Therapy Monitoring of Breast Cancer Patients by Dna/Rna Typing of Minimal Residual Cancer Cells

2000 ◽  
Vol 15 (1) ◽  
pp. 94-99 ◽  
Author(s):  
M. Giesing ◽  
F. Austrup ◽  
B. BÖckmann ◽  
G. Driesel ◽  
C. Eder ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Molecular Characterization ◽  
Therapy Monitoring ◽  
Breast Cancer Patients ◽  
Residual Cancer ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Clinical relevance, purification techniques and molecular characterization of minimal residual cancer cells (MRCC) is a controversial topic in the literature. An analytical concept including a novel isolation procedure and a panel of tests for DNA and RNA typing of MRCCs is described and clinically evaluated in this paper. The purification procedure exploiting the physical characteristics of MRCCs shows superior performance leading to >50% pure and viable tumor cells. Proof of the presence and purity of MRCCs in an isolated sample is given by multiparametric DNA typing (amplifications, mutations, losses of heterozygosity). On the basis of the proven presence of MRCCs tumor-relevant mRNAs can be adequately analyzed by normalized quantitative real-time RT-PCR. The molecular characterization of MRCCs isolated from blood of breast cancer patients could have a strong clinical impact on prognostication, drug targeting and therapy monitoring.

scholarly journals Co-delivery of siRNA and doxorubicin to cancer cells from additively manufactured implants

RSC Advances ◽  
2015 ◽  
Vol 5 (123) ◽  
pp. 101718-101725 ◽  
Author(s):  
Muwan Chen ◽  
Morten Ø. Andersen ◽  
Philipp Dillschneider ◽  
Chi-Chih Chang ◽  
Shan Gao ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Chitosan Nanoparticles ◽  
Clinical Problem ◽  
Residual Cancer ◽  
Load Bearing ◽  
Major Clinical Problem

Tumors in load bearing bones are a major clinical problem as recurrence is common after surgery. Void filling scaffolds that kill residual cancer cells by releasing chemotherapy and siRNA/chitosan nanoparticles may offer a solution to this problem.

scholarly journals Perioperative Period is a Critical Gap for Minimal Residual Cancer Cells Progression and Therapy: Biological and Molecular Based Evidences

2018 ◽  
Vol 3 (2) ◽  
pp. 1-13
Author(s):  
Anwar Tawfik Amin ◽  
Norio Shiraishi ◽  
Seigo Kitano
Keyword(s):  
Immune System ◽  
Cancer Cells ◽  
Solid Tumors ◽  
Perioperative Period ◽  
Review Article ◽  
Residual Cancer ◽  
Critical Gap ◽  
Surrounding Environment ◽  
Minimal Residual Cancer ◽  
Minimal Residual

Although surgery is the main treatment for solid tumors, it could enhance the growth and metastasis of minimal residual cancer. In this review article we have discussed the perioperative changes in cancer cells and surrounding environment as well as the alterations in the immune system. Several trials are ongoing to develop new diagnostic and therapeutic options for minimal residual cancer after surgery.

Sign in / Sign up

Export Citation Format

Share Document